Reliance Chemotex Q3 FY26: Margins Shine Despite Revenue Decline

The December quarter marked the lowest quarterly revenue for Reliance Chemotex in recent periods at ₹81.94 crores, down from ₹99.52 crores in Q2 FY26 and ₹92.23 crores in Q3 FY25. Despite this revenue contraction, the company demonstrated remarkable margin resilience, with operating margins expanding to 13.06% from 10.33% in the previous quarter. This margin improvement, coupled with lower interest costs and improved tax efficiency, helped cushion the bottom-line impact of declining sales. For the nine-month period ending December 2025, the company posted cumulative profits of ₹3.51 crores, representing a 59.55% increase over the corresponding period last year.

Financial Performance: Revenue Pressure Meets Margin Strength

Reliance Chemotex's Q3 FY26 performance reveals a tale of two narratives. On one hand, net sales declined 17.66% QoQ to ₹81.94 crores, the lowest quarterly revenue in the trailing twelve-month period. This represents an 11.16% decline compared to Q3 FY25, indicating both sequential and year-on-year weakness in demand. The revenue contraction appears to be driven by challenging market conditions in the textile sector, with reduced offtake from apparel manufacturers.

However, the company's operational efficiency showed marked improvement. Operating profit before depreciation, interest, tax and other income (PBDIT excluding OI) stood at ₹10.70 crores, translating to an operating margin of 13.06%. This represents a 273 basis point improvement QoQ from 10.33% and a substantial 335 basis point expansion YoY from 9.71%. The margin improvement suggests better cost management, potentially driven by favourable raw material prices or improved operational efficiencies at the company's spinning facilities.

Interest costs declined marginally to ₹6.32 crores from ₹5.88 crores in Q2 FY26, whilst depreciation remained stable at ₹3.70 crores. The company's tax rate normalised to 25.93% in Q3 FY26 after highly volatile rates in previous quarters, contributing to bottom-line stability. Profit before tax stood at ₹1.08 crores, nearly flat QoQ but up significantly from ₹0.12 crores in Q3 FY25.

On a nine-month basis for FY26, the company has generated net sales of ₹273.82 crores compared to ₹276.40 crores in the corresponding period of FY25, representing a marginal 0.93% decline. However, nine-month net profit improved substantially to ₹3.51 crores from ₹2.20 crores, driven by the significant margin expansion witnessed across the quarters. This demonstrates the company's ability to protect profitability even in a challenging revenue environment through operational discipline.

Operational Challenges: Weak Returns and High Leverage

Whilst margin performance has been encouraging, Reliance Chemotex continues to grapple with fundamental operational weaknesses that constrain its overall financial health. The company's return on equity (ROE) averaged just 7.27% over recent periods, with the latest ROE at a concerning 3.45%. This indicates that the company generates minimal returns on shareholders' capital, raising questions about capital efficiency and the sustainability of value creation.

Return on capital employed (ROCE) presents an even more worrying picture, averaging 9.74% with the latest figure at just 4.53%. This suggests that the company's core operations are generating inadequate returns relative to the capital invested in the business. For context, a textile manufacturing business operating at optimal efficiency should typically generate ROCE in the mid-teens or higher to justify the capital intensity of the industry.

The company's balance sheet reveals significant leverage concerns. As of March 2025, Reliance Chemotex carried long-term debt of ₹139.64 crores against shareholder funds of ₹137.28 crores, resulting in a debt-to-equity ratio exceeding 1.0. The company's net debt-to-equity ratio averaged 1.83 over recent periods, indicating substantial financial leverage. With an average debt-to-EBITDA ratio of 5.73, the company's debt burden is high relative to its cash generation capacity.

Interest coverage remains a concern, with the average EBIT-to-interest ratio at just 1.66x. This provides minimal cushion for servicing debt obligations, particularly if operating performance deteriorates. In Q3 FY26, interest costs of ₹6.32 crores consumed a significant portion of operating profits, limiting the funds available for growth investments or deleveraging.

Fixed assets stood at ₹275.19 crores as of March 2025, having declined from ₹278.61 crores in the previous year, suggesting limited capacity expansion. The company's current assets of ₹153.13 crores are offset by current liabilities of ₹167.95 crores, indicating negative working capital. This working capital position, combined with high debt levels, constrains the company's financial flexibility and ability to navigate industry downturns.

Industry Context: Navigating Textile Sector Headwinds

The Indian textile industry has faced multiple challenges in recent quarters, including subdued domestic demand, global economic uncertainty, and inventory corrections across the value chain. Synthetic yarn manufacturers like Reliance Chemotex have been particularly impacted by volatility in raw material prices and competitive pressures from imports. The company's declining revenue trajectory mirrors broader industry trends, with many textile manufacturers reporting muted growth.

However, Reliance Chemotex's margin expansion stands in contrast to industry trends, where most players have struggled to maintain profitability amidst cost pressures. This suggests company-specific operational improvements, potentially through better procurement practices, product mix optimisation, or cost rationalisation initiatives. The company's focus on synthetic and blended yarn provides some insulation from cotton price volatility, though it exposes the business to petrochemical feedstock price fluctuations.

The garments and apparels sector, which constitutes Reliance Chemotex's primary customer base, has witnessed tepid demand growth both domestically and in export markets. Inventory destocking by retailers and subdued consumer sentiment have contributed to reduced yarn offtake. Looking ahead, the industry's recovery trajectory remains uncertain, contingent on improvements in end-consumer demand and stabilisation of input costs.

Peer Comparison: Valuation Discount Reflects Concerns

Reliance Chemotex's financial metrics and valuation multiples reveal its positioning within the garments and apparels sector. Compared to peers, the company demonstrates certain relative strengths but also significant weaknesses that justify its valuation discount.

Reliance Chemotex trades at a P/E ratio of 22.12x, which appears reasonable relative to peers excluding the highly leveraged Digjam. However, the company's price-to-book value of 0.76x suggests the market values its assets below book value, reflecting concerns about asset quality and return generation. This discount is justified given the company's weak ROE of 7.27%, which ranks amongst the higher end of the peer group but remains inadequate in absolute terms.

The company's debt-to-equity ratio of 1.83 is significantly higher than most peers, with only Digjam carrying comparable leverage. This elevated debt burden, combined with weak interest coverage, contributes to the valuation discount. The dividend yield of 0.38% is modest, reflecting the company's limited cash generation and need to conserve capital for debt servicing.

Reliance Chemotex's ROE of 7.27% compares favourably to most peers, suggesting relatively better capital efficiency within a weak peer group. However, this is insufficient to justify premium valuations, particularly given the high leverage that magnifies financial risk. The company's market capitalisation of ₹108.00 crores positions it as the largest within this micro-cap peer group, though this provides limited liquidity advantages for investors.

Valuation Analysis: Discount Justified by Weak Fundamentals

At the current price of ₹144.90, Reliance Chemotex trades at a P/E ratio of 22.12x based on trailing twelve-month earnings. This valuation appears reasonable on the surface but masks underlying concerns about earnings quality and sustainability. The company's price-to-book value of 0.76x indicates the market is assigning a discount to the company's net asset value, reflecting scepticism about the productive capacity and return-generating potential of these assets.

The enterprise value-to-EBITDA multiple of 8.62x appears attractive compared to historical textile sector averages, whilst the EV-to-sales ratio of 0.97x suggests the company is valued at less than one times revenue. However, these seemingly attractive multiples must be viewed in the context of weak returns on capital and high leverage. The company's EV-to-capital employed ratio of 0.92x indicates the market values the entire business below the capital invested, a clear signal of value destruction concerns.

The PEG ratio of 0.25 suggests the stock may be undervalued relative to growth expectations, though this metric has limited reliability given the company's volatile earnings trajectory. The dividend yield of 0.38% provides minimal income support, with the latest dividend of ₹0.50 per share representing a payout ratio of 23.55%. This conservative payout reflects the company's need to retain cash for debt servicing and working capital requirements.

The stock has declined 31.54% from its 52-week high of ₹211.65, reached in the previous fiscal year, whilst trading 31.55% above its 52-week low of ₹110.15. This positioning in the middle of the annual range reflects the market's uncertainty about the company's prospects. The valuation assessment classifies the stock as "Very Attractive," though this appears to reflect low absolute multiples rather than strong fundamental quality.

Shareholding Pattern: Stable Promoter Base, Negligible Institutions

Reliance Chemotex's shareholding structure has remained remarkably stable over recent quarters, with promoter holding steady at 67.68% across the last five quarters through December 2025. The promoter group, led by Modern Fibotex India Limited with a 41.36% stake, demonstrates strong commitment to the business with zero pledging of shares. Other significant promoter entities include Rahul Shroff (4.89%), A S Chemotex Private Limited (4.05%), and A R Fibtex Private Limited (3.98%).

The absence of institutional participation is striking and concerning. Foreign institutional investors (FIIs) hold virtually no stake, with a brief 0.03% holding in June 2025 that has since been exited. Mutual funds, insurance companies, and other domestic institutional investors (DIIs) are entirely absent from the shareholding structure. This complete lack of institutional interest reflects the company's micro-cap status, weak fundamentals, and limited liquidity, which make it unsuitable for institutional portfolios.

Non-institutional shareholders, comprising retail investors and high-net-worth individuals, hold the remaining 32.32%. The stability in this holding suggests limited trading activity and a relatively illiquid stock. The absence of institutional buying despite the stock's recent decline indicates professional investors remain unconvinced about the company's turnaround prospects or risk-reward profile.

Stock Performance: Severe Underperformance Across Timeframes

Reliance Chemotex's stock price performance has been deeply disappointing across most timeframes, significantly underperforming both the broader market and its sectoral peers. The stock has generated negative alpha across virtually all meaningful investment horizons, indicating consistent wealth destruction for shareholders.

Over the past year, the stock has declined 24.90% whilst the Sensex gained 10.37%, resulting in a negative alpha of 35.27 percentage points. The two-year performance is even more concerning, with the stock down 42.10% compared to the Sensex's 17.61% gain, translating to a negative alpha of 59.71 percentage points. This sustained underperformance reflects deteriorating fundamentals, weak earnings growth, and declining investor confidence.

Recent short-term performance shows some stabilisation, with the stock gaining 15.09% over the past week and 5.77% over the past month, outperforming the market. However, this appears to be a technical bounce from oversold levels rather than a fundamental reversal. The year-to-date gain of 8.58% for FY26 provides limited comfort given the stock's positioning well below historical highs.

The stock's beta of 1.03 indicates it generally moves in line with the market, though the severe underperformance suggests company-specific issues rather than broader market trends. With a volatility of 43.95% over the past year, the stock exhibits high risk, whilst the negative risk-adjusted return of -0.57 categorises it as a "high risk, low return" investment. The stock currently trades below all major moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), indicating persistent technical weakness.

Investment Thesis: Weak Fundamentals Outweigh Valuation Appeal

Reliance Chemotex presents a complex investment case characterised by attractive valuation multiples that are offset by weak fundamental quality and concerning operational trends. The company's proprietary investment score of 31 out of 100 places it firmly in "SELL" territory, reflecting the preponderance of negative factors over positives.

The valuation assessment of "Very Attractive" based on low absolute multiples (P/E of 22.12x, P/BV of 0.76x) appears superficially appealing. However, this valuation discount is entirely justified by the company's below-average quality grade and weak return metrics. With an average ROCE of 9.74% and latest ROCE of just 4.53%, the company is destroying value rather than creating it. The high debt burden (debt-to-equity of 1.83) and weak interest coverage (1.66x) compound these concerns.

The financial trend assessment of "Flat" for Q3 FY26 reflects the mixed performance—declining revenues offset by improving margins. Whilst the nine-month profit growth of 59.55% appears impressive, this comes off a low base and doesn't address the underlying revenue weakness. The technical trend of "Mildly Bearish" suggests continued downward pressure, with the stock trading below all major moving averages.

Key Strengths & Risk Factors

Outlook: What to Watch